Literature DB >> 17601397

New antiplatelet therapies for acute coronary syndromes.

Jonathan D Rich1, Stephen D Wiviott.   

Abstract

Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17601397     DOI： 10.1007/bf02938379

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  52 in total

1.  Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.

Authors:  Robert F Storey; Robert G Wilcox; Stan Heptinstall
Journal:  Platelets       Date:  2002-11       Impact factor: 3.862

2.  High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

Authors:  Dominick J Angiolillo; Antonio Fernández-Ortiz; Esther Bernardo; Celia Ramírez; Manel Sabaté; Camino Bañuelos; Rosana Hernández-Antolín; Javier Escaned; Raul Moreno; Fernando Alfonso; Carlos Macaya
Journal:  Eur Heart J       Date:  2004-11       Impact factor: 29.983

3.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

Authors:  Thomas A Clarke; Lucy A Waskell
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

4.  Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.

Authors:  Andrew J Leger; Suzanne L Jacques; Jehangir Badar; Nicole C Kaneider; Claudia K Derian; Patricia Andrade-Gordon; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2006-02-27       Impact factor: 29.690

Review 5.  Mechanisms of action and targets for actual and future antiplatelet drugs.

Authors:  Kathleen Freson; Chantal Thys; Christine Wittevrongel; Chris Van Geet
Journal:  Mini Rev Med Chem       Date:  2006-06       Impact factor: 3.862

6.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.

Authors:  Paul A Gurbel; Kevin P Bliden; Kevin M Hayes; Jason A Yoho; William R Herzog; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-05-03       Impact factor: 24.094

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

9.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.

Authors:  A H Ingall; J Dixon; A Bailey; M E Coombs; D Cox; J I McInally; S F Hunt; N D Kindon; B J Teobald; P A Willis; R G Humphries; P Leff; J A Clegg; J A Smith; W Tomlinson
Journal:  J Med Chem       Date:  1999-01-28       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.